Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • statins

    - PMLiVE

    GSK’s Blenrep combination recommended by NICE to treat multiple myeloma

    The decision means that eligible patients in England will be the first in the world to access the combination

    - PMLiVE

    NICE recommends Gideon Richter’s Ryeqo as first daily pill for endometriosis

    Around 1,000 patients could benefit from the relugolix combination therapy every year

    - PMLiVE

    Roche’s Genentech granted FDA approval for TNKase in acute ischaemic stroke

    TNKase is the first stroke medicine to be approved by the regulator in almost three decades

    - PMLiVE

    Amgen’s Blincyto recommended by NICE for new adult leukaemia indication

    Up to 50% of acute lymphoblastic leukaemia patients will relapse after initial treatment

    - PMLiVE

    AstraZeneca receives NICE recommendations for lung cancer drugs Tagrisso and Imfinzi

    More than 49,000 people are diagnosed with lung cancer in the UK each year

    - PMLiVE

    NICE recommends Santhera’s Duchenne muscular dystrophy drug Agamree

    Approximately 1,700 patients with the muscle-wasting disorder in England are expected to benefit from the decision

    - PMLiVE

    NICE recommends Immunocore’s Kimmtrak as first drug for aggressive eye cancer

    More than 100 patients are expected to be eligible for the treatment every year

    - PMLiVE

    NICE recommends Blueprint Medicines’ Ayvakyt to treat rare blood disorder

    Systemic mastocytosis affects approximately one in every 10,000 people in the UK

    - PMLiVE

    Pfizer’s Elrexfio recommended by NICE to treat relapsed and refractory multiple myeloma

    Approximately 5,000 people are diagnosed with the disease every year in England

    - PMLiVE

    AstraZeneca’s Voydeya recommended by NICE to treat rare blood disorder PNH

    The drug has been recommended for use alongside the company’s C5 inhibitors

    - PMLiVE

    Ipsen’s Iqirvo recommended by NICE to treat rare liver disease primary biliary cholangitis

    The disease affects approximately 25,000 people in the UK, the majority of whom are women

    - PMLiVE

    Johnson & Johnson receives updated NICE recommendation for Tecvayli in multiple myeloma

    Approximately 5,900 new cases of the blood cancer are diagnosed every year in the UK

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links